---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-056002"
form_type: "8-K"
ticker: null
cik: "0001621443"
company_name: "Zynerba Pharmaceuticals, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:08:55.046253+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zynerba gets 180-day Nasdaq bid-price extension, transfers to Capital Market

## Summary
- Nasdaq granted 180-day extension until Oct 30, 2023 to regain $1 bid price compliance.
- Company's stock transferred from Nasdaq Global Market to Capital Market effective May 4, 2023.
- Will consider reverse stock split to cure deficiency if needed.
- Previously received deficiency notice Nov 1, 2022; failed to cure by May 1, 2023.

## SEC filing metadata
- accession: 0001104659-23-056002
- form_type: 8-K
- cik: 0001621443
- company_name: Zynerba Pharmaceuticals, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621443/000110465923056002/0001104659-23-056002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621443/000110465923056002/tm2314618d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-056002
- JSON: https://secwatch.observer/filing/0001104659-23-056002.json
- Plain text: https://secwatch.observer/filing/0001104659-23-056002.txt

## Key facts
- Listing & Compliance Notices
  Zynerba Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: May 2, 2023, Nasdaq notified the Company that it had granted the Company an additional 180 calendar day period, or until October 30, 2023 (the “ Extended Compliance Date ”), to regain compliance with the Bid Price Rule. Nasdaq’s determination was based on, among other things, (1) the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing requirements for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and (2) the Company’s written notice of its intention to cure the deficiency by effecting a reverse stock sp
  evidence_url: https://www.sec.gov/Archives/edgar/data/1621443/000110465923056002/0001104659-23-056002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.